NCBS Bengaluru Decodes How Persister Cancer Cells Survive
Understanding the fundamental drivers of cancer drug resistance remains a major challenge in modern clinical oncology. While standard therapies eliminate most tumor cells, resilient persister cells frequently survive to drive tumor recurrence. Recently, researchers at the National Centre for Biological Sciences in Bengaluru developed an algorithm named Power-Seek. This innovative tool accurately identifies drug-tolerant persister cells using standard single-cell RNA sequencing data.
Understanding Non-Genetic Cancer Drug Resistance
Traditionally, oncologists attribute therapeutic failure to permanent genetic mutations. However, accumulating evidence reveals that reversible changes in gene expression enable malignant cells to withstand aggressive treatment. Specifically, certain cells activate protective transcriptional programs before drug exposure occurs. These transcriptional states persist through subsequent cell divisions, creating a robust form of cellular memory. Consequently, genetically identical tumor cells often respond differently to identical chemotherapy regimens. Previously, identifying these memory genes required laborious lineage tracking across multiple generations of cells.
How Power-Seek Detects Cellular Memory
To overcome this clinical barrier, NCBS scientists utilized random matrix theory to uncover hidden transcriptional signatures. Because related cells share ancestral expression patterns, persistent gene states generate distinct power-law signatures. Therefore, Power-Seek can identify drug-tolerant populations from a single clinical biopsy snapshot. The research team initially validated the tool on established melanoma datasets. Subsequently, they applied Power-Seek to clinical breast cancer specimens with remarkable success. Interestingly, both cancer types displayed overlapping functional pathways among their memory genes.
Clinical Implications for Oncology Practice
This breakthrough provides meaningful opportunities for tailored cancer management. Furthermore, the ability to pinpoint persister states prior to therapy could guide early combination regimens. In addition, targeting shared cellular memory pathways might prevent cross-resistance across diverse solid tumors. As a result, future oncology workflows may integrate single-cell algorithms to anticipate therapeutic failure early.
Frequently Asked Questions
Q1: What are cancer memory genes?
Cancer memory genes are specific genes whose persistent expression states survive cell division, allowing tumor cells to tolerate therapy without acquiring permanent DNA mutations.
Q2: How does the Power-Seek algorithm aid clinical oncology?
Power-Seek analyzes single-cell RNA sequencing data from a single biopsy sample to detect resilient cell populations before treatment begins.
Q3: Which cancer types were evaluated in the NCBS study?
The researchers successfully validated the algorithm using melanoma lineage datasets and primary clinical breast cancer tissue samples.
To explore more training options for medical practitioners, you can visit OC Academy.
References
- Bengaluru researchers pin point cancer cells that survive drugs - ETHealthworld
- Single-cell snapshots identify gene states linked to treatment tolerance without lineage tracking - Cell Systems
- Identifying memory gene expression from single sample scRNA-seq data using power law signatures - bioRxiv
